{"id":21420,"date":"2023-08-24T00:15:00","date_gmt":"2023-08-24T00:15:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4191340_AE91340_0"},"modified":"2023-08-24T00:15:00","modified_gmt":"2023-08-24T00:15:00","slug":"everest-medicines-announces-interim-results-for-first-half-of-2023","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=21420","title":{"rendered":"Everest Medicines Announces Interim Results for First Half of 2023"},"content":{"rendered":"<p><span class=\"xn-location\">SHANGHAI<\/span>, <span class=\"xn-chron\">Aug. 24, 2023<\/span> \/PRNewswire\/ &#8212; Everest Medicines (HKEX 1952.HK, &#8220;Everest&#8221;, or the &#8220;Company&#8221;), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2023, along with a corporate update.<\/p>\n<p>&#8220;We are pleased to have achieved a number of critical milestones during the first half of 2023, propelling Everest to a commercial stage biopharma,&#8221; commented Rogers Yongqing Luo, CEO of Everest Medicines. &#8220;At the end of July, we successfully took the critical step of launching our first therapeutic drug in <span class=\"xn-location\">China<\/span>, Xerava<sup>\u00ae<\/sup>, which is the world&#8217;s first fluocycline antibiotic for the treatment of multi-drug resistant infections. To support Xerava&#8217;s launch, we have built a lean and efficient commercial team of highly experienced professionals, which we will gradually scale up as we prepare for additional product debuts. Over the next 18-24 months, we expect to have three additional products approved in <span class=\"xn-location\">China<\/span>.&#8221;&nbsp;<\/p>\n<p>&#8220;Being one of very few biotech companies with a substantial lineup of products prepared for launch over the next two years clearly demonstrates our expertise in selecting and commercializing promising drug candidates. We expect to receive NDA approvals from both <span class=\"xn-location\">China<\/span> and <span class=\"xn-location\">Singapore<\/span> in the second half of 2023 for Nefecon<sup>\u00ae<\/sup>, our first-in-disease treatment for adults with primary immunoglobulin A nephropathy (IgAN) and launch Nefecon<sup>\u00ae<\/sup> broadly in <span class=\"xn-location\">China<\/span> in early 2024. We will also continue to broaden our product pipeline through our dual approach of in-licensing and internal discovery, targeting underserved conditions and areas of high unmet need with innovative and differentiated therapies. Through a series of measures to improve operational efficiency and restructure our strategic focus, we have significantly reduced expenses across different functions and narrowed net loss in the first six months of this year by more than a third compared to a year ago. This will allow Everest to continue to generate value for our stakeholders and shareholders,&#8221; said Mr. Luo.&nbsp;<\/p>\n<p><b>Recent Product Highlights and Anticipated Milestones<\/b><\/p>\n<p><b>INFECTIOUS DISEASE PORTFOLIO<\/b><\/p>\n<p><b><i>Eravacycline (Xerava<sup>\u00ae<\/sup>), <\/i><\/b><i>is the world&#8217;s first Fluorocycline antibiotic for the treatment of infections caused by gram negative, gram positive and anaerobic pathogens including multidrug-resistant (&#8220;MDR&#8221;) isolates. Its current approved indication is cIAI in adult patients.<\/i>&nbsp;<\/p>\n<ul type=\"disc\">\n<li>Achievements during the Reporting Period:<\/li>\n<ul type=\"disc\">\n<li>On <span class=\"xn-chron\">March 16, 2023<\/span>, the Company announced that <span class=\"xn-location\">China&#8217;s<\/span>&nbsp;NMPA approved its NDA for Xerava<sup>\u00ae<\/sup> in the treatment of cIAI in adult patients, marking it the first product to be commercialized by the Company in <span class=\"xn-location\">China<\/span>.<\/li>\n<\/ul>\n<li>Post-Reporting Period achievements and expected milestones:<\/li>\n<ul type=\"disc\">\n<li>On <span class=\"xn-chron\">July 26<\/span>, 2023,&nbsp;Xerava<sup>\u00ae<\/sup> was successfully launched in <span class=\"xn-location\">China<\/span> with its first prescriptions issued at Huashan Hospital affiliated to Fudan University. The commercialization of Xerava<sup>\u00ae <\/sup>in <span class=\"xn-location\">China<\/span> marks the Company&#8217;s transformation into a commercial-stage innovative biopharmaceutical company.<\/li>\n<li>We expect&nbsp;NDA approval for eravacycline for the treatment of cIAI in the <span class=\"xn-location\">Taiwan<\/span> region in 2023.<\/li>\n<\/ul>\n<\/ul>\n<p><b><i>Taniborbactam<\/i><\/b><i>&nbsp;is a beta-lactamase inhibitor (&#8220;BLI&#8221;) that, in combination with cefepime, may offer a potential treatment option for patients with serious bacterial infections caused by difficult-to-treat resistant gram-negative bacteria, most notably carbapenem-resistant Enterobacterales (&#8220;CRE&#8221;) and carbapenem-resistant Pseudomonas aeruginosa (&#8220;CRPA&#8221;).<\/i><\/p>\n<ul type=\"disc\">\n<li>Post-Reporting Period achievements and expected milestones:<\/li>\n<ul type=\"disc\">\n<li>On <span class=\"xn-chron\">15 August 2023<\/span>, our partner&nbsp;Venatorx Pharmaceuticals announced that the US FDA has accepted the NDA for cefepime-taniborbactam, an investigational beta-lactam\/beta-lactamase inhibitor (BL\/BLI) antibiotic for the potential treatment of adult patients with complicated urinary tract infections(&#8220;cUTI&#8221;), including pyelonephritis. The FDA has granted priority review of the NDA with a Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) target action date of <span class=\"xn-chron\">February 22, 2024<\/span>.<\/li>\n<\/ul>\n<\/ul>\n<p><b><i>EVER206 (also known as SPR206)<\/i><\/b>, <i>is a potentially best-in-class, novel polymyxin derivative designed to reduce toxicity, especially nephrotoxicity, compared to levels observed clinically with polymyxin B and colistin.<\/i><\/p>\n<ul type=\"disc\">\n<li>Achievements during the Reporting Period:<\/li>\n<ul type=\"disc\">\n<li>On <span class=\"xn-chron\">January 18, 2023<\/span>, the Company announced&nbsp;topline results from a <span class=\"xn-location\">China<\/span> phase 1 study on healthy subjects demonstrating that EVER206 is well-tolerated with no evidence of acute kidney injury and no new safety signals on healthy subjects with dose ranges applied in the study. The pharmacokinetics of healthy subjects in <span class=\"xn-location\">China<\/span> were comparable to the results of the overseas phase I study (SPR206-101) and the safety profile was also similar to the results from the overseas Phase I trial, supporting the Company&#8217;s plans to initiate next-phase clinical development in <span class=\"xn-location\">China<\/span>.<\/li>\n<\/ul>\n<\/ul>\n<p><b>RENAL PORTFOLIO<\/b><\/p>\n<p><b><i>Nefecon<sup>\u00ae<\/sup><\/i><\/b><i>, our anchor drug candidate in the renal therapeutic area, is a patented oral, delayed release formulation of budesonide in development for the treatment of IgAN.<\/i><\/p>\n<ul type=\"disc\">\n<li>Achievements during the Reporting Period:<\/li>\n<ul type=\"disc\">\n<li>On <span class=\"xn-chron\">February 10, 2023<\/span>, <span class=\"xn-location\">South Korea&#8217;s<\/span> Ministry of Food and Drug Safety (&#8220;MFDS&#8221;) granted Global Innovative product on Fast Track (&#8220;GIFT&#8221;) designation to Nefecon<sup>\u00ae<\/sup> for the treatment of primary IgAN. <span class=\"xn-location\">South Korea&#8217;s<\/span> GIFT program was launched in <span class=\"xn-chron\">September 2022<\/span> to further accelerate review timeframes, especially for groundbreaking products. Nefecon<sup>\u00ae<\/sup> is the second product overall and the first non-oncology product included in MFDS&#8217;s GIFT program. Inclusion in the GIFT program is expected to accelerate regulatory review time by 25% and allow for rolling review.<\/li>\n<li>On <span class=\"xn-chron\">March 12, 2023<\/span>, our partner&nbsp;Calliditas Therapeutics AB (&#8220;Calliditas&#8221;) reported positive topline results from a Phase 3 NefIgArd Trial evaluating Nefecon<sup>\u00ae<\/sup> in the treatment of IgAN. The trial met its primary endpoint with Nefecon<sup>\u00ae<\/sup> demonstrating a highly statistically significant benefit over placebo (p value &lt;0.0001) in estimated glomerular filtration rate (&#8220;eGFR&#8221;) over a 2-year period, which included nine months of treatment period with either Nefecon<sup>\u00ae<\/sup> or placebo, then followed by 15 months off drug, observational follow-up period. The primary endpoint, time-weighted average change from baseline in eGFR over the 2-year period, demonstrated a 5.05 mL\/min\/<span class=\"xn-money\">1.73 m<\/span><sup>2<\/sup> eGFR treatment benefit in favor of Nefecon<sup>\u00ae<\/sup> compared to placebo over two years was observed &nbsp;(p&lt;0.0001). Time-weighted average change from baseline in eGFR over the 2-year period was -2.47 mL\/min\/<span class=\"xn-money\">1.73 m<\/span><sup>2<\/sup> for Nefecon<sup>\u00ae<\/sup> 16mg group versus -7.52 mL\/min\/<span class=\"xn-money\">1.73 m<\/span><sup>2<\/sup> for placebo group.<\/li>\n<li>On <span class=\"xn-chron\">April 6, 2023<\/span>, Singapore Health Sciences Authority accepted the NDA for Nefecon<sup>\u00ae<\/sup> for the treatment of IgAN in adults at risk of disease progression. The Company expects to receive NDA approval in <span class=\"xn-location\">Singapore<\/span> in 2023.<\/li>\n<li>In <span class=\"xn-chron\">June 2023<\/span>, our partner Calliditas presented more complete data from the NefIgArd Phase 3 Study at the European Renal Association \u2014 European Dialysis and Transplant Association Congress (ERA-EDTA). Most noteworthy is that data showed at 24 months, eGFR was reduced by 6.11 mL\/min\/<span class=\"xn-money\">1.73 m<\/span><sup>2<\/sup> from baseline in the Nefecon<sup>\u00ae<\/sup> arm compared with 12 mL\/min\/<span class=\"xn-money\">1.73 m<\/span><sup>2<\/sup> reduction in the placebo arm, demonstrating 50% less loss of kidney function. The reduction in urine protein creatinine ratio (&#8220;UPCR&#8221;) was also durable, with a 30.7% decrease in UPCR in the Nefecon<sup>\u00ae<\/sup> arm even after 15 months off drug compared with only 1% reduction in the placebo arm. Another analysis of the effect of durability of proteinuria reduction showed a 41% reduction in time-averaged UPCR over 12\u201324 months compared with placebo (95% CI 32-49%, p&lt;0.0001). As for the hematuria treatment, the proportion of patients with microhematuria in the Nefecon<sup>\u00ae<\/sup> arm fell to 40.5% from 66.5% baseline while the placebo arm only decreased to 61.2% from 67.8% baseline. This data was published in<i> The Lancet<\/i> in <span class=\"xn-chron\">August 2023<\/span>.<\/li>\n<li>On <span class=\"xn-chron\">June 21, 2023<\/span>, our partner Calliditas announced the submission of a supplemental New Drug Application (&#8220;sNDA&#8221;) to the U.S. Food and Drug Administration(&#8220;FDA&#8221;) seeking full approval of TARPEYO<sup>\u00ae<\/sup> (brand name of Nefecon in the US) delayed release capsules for the entire study population from the Phase 3 NefIgArd study. The sNDA submission is based on the full data set from the Phase 3 NefIgArd clinical trial. The trial met its primary endpoint, with TARPEYO<sup>\u00ae<\/sup> demonstrating a highly statistically significant benefit over placebo (p value &lt; 0.0001) in eGFR over the two-year period of 9 months of treatment with TARPEYO<sup>\u00ae<\/sup> or placebo and 15 months of follow-up off drug. Calliditas announced FDA accepted the sNDA with priority review on <span class=\"xn-chron\">Aug. 18<\/span>.<\/li>\n<\/ul>\n<li>Post-Reporting Period achievements and expected milestones:<\/li>\n<ul type=\"disc\">\n<li>On <span class=\"xn-chron\">August 1, 2023<\/span>, the Company announced the completion of patient enrollment for the <span class=\"xn-location\">China<\/span> open-label extension (&#8220;cOLE&#8221;) of the Phase 3 NefIgArd study. The cOLE study offers an additional 9 months of treatment with Nefecon<sup>\u00ae<\/sup> to all qualifying patients who have completed the NefIgArd study and will evaluate the efficacy and safety of extended and repeated Nefecon<sup>\u00ae<\/sup> treatment in patients with IgAN.<\/li>\n<li>We expect to receive NDA approval for Nefecon<sup>\u00ae<\/sup> in the treatment of primary IgAN in mainland <span class=\"xn-location\">China<\/span> and <span class=\"xn-location\">Singapore<\/span> in 2023.<\/li>\n<li>We expect to file an NDA for Nefecon<sup>\u00ae<\/sup> in the treatment of IgAN in <span class=\"xn-location\">South Korea<\/span>, <span class=\"xn-location\">Hong Kong<\/span>, <span class=\"xn-location\">Macau<\/span> and <span class=\"xn-location\">Taiwan<\/span> region in 2023.<\/li>\n<\/ul>\n<\/ul>\n<p><b>AUTOIMMUNE DISEASE PORTFOLIO<\/b><\/p>\n<p><b><i>Etrasimod<\/i><\/b><b><i>, <\/i><\/b><i>is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5. In addition to UC, it is being investigated for a range of other immuno-inflammatory diseases.<\/i><\/p>\n<ul type=\"disc\">\n<li>Achievements during the Reporting Period:<\/li>\n<ul type=\"disc\">\n<li>On <span class=\"xn-chron\">May 17, 2023<\/span>, the Company announced the completion of patient enrollment in a multi-region, multi-center Phase 3 clinical trial of etrasimod in <span class=\"xn-location\">Asia<\/span> for the treatment of moderate-severe active ulcerative colitis (&#8220;UC&#8221;).<\/li>\n<\/ul>\n<li>Post-Reporting Period achievements and expected milestones:<\/li>\n<ul type=\"disc\">\n<li>Our licensing partner, Pfizer Inc. (NYSE: PFE) (&#8220;Pfizer&#8221;) expects to receive FDA&#8217;s decision for etrasimod for individuals living with moderately-to-severely active UC in the second half of 2023. The NDA was accepted by the U.S FDA in <span class=\"xn-chron\">December 2022<\/span>.<\/li>\n<li>We expect to readout 12-week induction of clinical remission data of etrasimod for the treatment of UC from the Asia Phase 3 clinical trial and discuss the potential regulatory filing strategy with relevant regulatory authorities in 2023.<\/li>\n<\/ul>\n<\/ul>\n<p><b>mRNA PLATFORM<\/b><\/p>\n<p><b><i>EVER-COVID19-M1.2,<\/i><\/b>&nbsp;<i>is an Omicron-targeting bivalent COVID-19 booster vaccine candidate.<\/i><\/p>\n<ul type=\"disc\">\n<li>Achievements during the Reporting Period:<\/li>\n<ul type=\"disc\">\n<li>Leveraging our clinically validated mRNA platform, the Company is developing an Omicron-containing bivalent booster candidate, EVER-COVID19-M1.2. The Company has initiated rolling data submissions for its Investigational New Drug (IND) application in <span class=\"xn-location\">China<\/span>.<\/li>\n<\/ul>\n<\/ul>\n<p><b>Commercialization<\/b><\/p>\n<ul type=\"disc\">\n<li>The Company is committed to making its new therapeutics available to healthcare providers and patients as soon as possible. We have dedicated significant resources for the successful launch of Xerava<sup>\u00ae<\/sup> and facilitate our transition into a commercial-stage company. We have built a lean and efficient commercial team of highly experienced professionals covering two key therapeutic areas, infectious disease and renal diseases. As of <span class=\"xn-chron\">June 30, 2023<\/span>, our commercial team has 138 members, including key employees across sales, marketing, market access, medical affairs, distribution and commercial excellence.<\/li>\n<li>The Company also established multiple partnerships with <span class=\"xn-location\">China&#8217;s<\/span> leading pharmaceutical distributors, including SPH Keyuan Xinhai Pharmaceutical Co., Ltd., Sinopharm Group, Guangzhou Pharmaceuticals Co., Ltd., Chongqing Pharmaceutical Group and Shanghai Pharmaceutical Co., Ltd. Under these partnerships, we will be able to leverage their industry-leading import and channel distribution networks to accelerate the commercialization of Xerava<sup>\u00ae<\/sup> in <span class=\"xn-location\">China<\/span>.<\/li>\n<li>Nefecon<sup>\u00ae<\/sup> is expected to be the second product the Company commercializes in <span class=\"xn-location\">China<\/span>. In <span class=\"xn-chron\">April 2023<\/span>, we introduced Nefecon<sup>\u00ae<\/sup> in <span class=\"xn-location\">China&#8217;s<\/span> Hainan Boao Pilot Zone to provide Chinese patients with IgAN early access to this innovative and first-in-disease therapy. Our early access program was well-received with over 500 patients signed up, highlighting the substantial unmet clinical needs of IgAN patients in <span class=\"xn-location\">China<\/span>. Given the high prevalence of IgAN in <span class=\"xn-location\">China<\/span>, our team is working diligently to have Nefecon<sup>\u00ae<\/sup> included in insurance programs to boost its affordability and accessibility, helping to alleviate patients&#8217; financial burden. As a result, in <span class=\"xn-chron\">May 2023<\/span>, the imported version of Nefecon<sup>\u00ae<\/sup> was added to the Beijing Puhui Health Insurance Program&#8217;s 2023 New Reimbursement Drug List of Specialized Medicines, as well as other local insurance programs such as Kunming City and <span class=\"xn-location\">Shanxi Province<\/span>. We expect to receive the NDA decision from <span class=\"xn-location\">China&#8217;s<\/span> NMPA in the second half of 2023 and launch Nefecon<sup>\u00ae<\/sup> broadly in <span class=\"xn-location\">China<\/span> in early 2024.<\/li>\n<\/ul>\n<p><b>Discovery<\/b><\/p>\n<ul type=\"disc\">\n<li>Our discovery pipeline focuses on novel targets for the treatment of renal diseases, and we expect to file an IND to enter clinical trials for our most advanced program in 2024. Additionally, with our clinically validated mRNA platform, we are advancing the discovovery and development of prophylactic vaccines for infectious diseases as well as therapeutic cancer vaccines for solid tumors.<\/li>\n<\/ul>\n<p><b>Business Development<\/b><\/p>\n<ul type=\"disc\">\n<li>Our business development efforts focus on renal diseases and autoimmune disorders. We look to continue to bolster our leadership position in these areas by expanding our pipeline and ecosystem through a combination of internal discovery and in-licensing. We are actively engaged in finding business partnerships in these disease areas.<\/li>\n<li>As we previously reported, in <span class=\"xn-chron\">August 2022<\/span> Immunomedics, Inc. (&#8220;Immunomedics&#8221;), a wholly-owned subsidiary of Gilead Sciences, Inc., agreed to acquire the Company&#8217;s rights to Trodelvy<sup>\u00ae<\/sup> for total consideration of up to <span class=\"xn-money\">US$455 million<\/span>, including <span class=\"xn-money\">US$280 million<\/span> in upfront payments. The Company received the full upfront payments in late 2022 and in the first quarter of 2023, strengthening our balance sheet and empowering us to advance the development of products in our core therapeutic areas.<\/li>\n<\/ul>\n<p><b>Future Development<\/b><\/p>\n<ul type=\"disc\">\n<li>We will continue to pursue regulatory approvals for our innovative drug candidates, applying our effective dual approach of in-licensing and internal discovery to expand our existing robust pipeline. In the near-term, we expect to receive NDA approvals in <span class=\"xn-location\">China<\/span> for three additional products, Nefecon<sup>\u00ae<\/sup>, etrasimod, and cefepime-taniborbactam. Notably, we are one of very few biotech companies expected to launch a broad lineup of products in the near term.<\/li>\n<li>Given the anticipated NDA approvals mentioned above, we have assembled a talented commercial team for the launch of Xerava<sup>\u00ae<\/sup> and Nefecon<sup>\u00ae<\/sup>. We will expand the team later this year as Nefecon<sup>\u00ae<\/sup>&#8216;s debut approaches, as well as in 2024 to establish deeper and broader hospital coverage.<\/li>\n<\/ul>\n<p><b>Financial Highlights<\/b><\/p>\n<p><b><i>IFRS Numbers:<\/i><\/b><\/p>\n<ul type=\"disc\">\n<li>Revenue increased by <span class=\"xn-money\">RMB7.9 million<\/span> to <span class=\"xn-money\">RMB8.9 million<\/span> for the six months ended <span class=\"xn-chron\">30 June 2023<\/span> from the same period of a year ago, primarily due to the sales of Xerava and Trodelvy<sup>\u00ae<\/sup> during transition period with Gilead in <span class=\"xn-location\">Singapore<\/span>.<\/li>\n<li>Research and development (&#8220;R&amp;D&#8221;) expenses decreased by <span class=\"xn-money\">RMB57.0 million<\/span> from <span class=\"xn-money\">RMB345.5 million<\/span> for the six months ended <span class=\"xn-chron\">30 June 2022<\/span> to <span class=\"xn-money\">RMB288.5 million<\/span> for the six months ended <span class=\"xn-chron\">30 June 2023<\/span>, primarily due to (i) a number of our drug candidates have completed clinical trials and advanced to regulatory submission or commercial stages; and (ii) the transfer of Trodelvy<sup>\u00ae<\/sup> clinical development activities to Gilead.<\/li>\n<li>General and administrative expenses decreased by <span class=\"xn-money\">RMB35.8 million<\/span> from <span class=\"xn-money\">RMB118.9 million<\/span> for the six months ended <span class=\"xn-chron\">30 June 2022<\/span> to <span class=\"xn-money\">RMB83.1 million<\/span> for the six months ended <span class=\"xn-chron\">30 June 2023<\/span>, mainly due to organization optimization and rationalization, and associated decrease in share-based compensation expenses.<\/li>\n<li>Distribution and selling expenses decreased by <span class=\"xn-money\">RMB84.1 million<\/span> from <span class=\"xn-money\">RMB148.2 million<\/span> for the six months ended <span class=\"xn-chron\">30 June 2022<\/span> to <span class=\"xn-money\">RMB64.1 million<\/span> for the six months ended <span class=\"xn-chron\">30 June 2023<\/span>, primarily due to the transfer of Trodelvy<sup>\u00ae<\/sup>-related commercial activities to Gilead and related optimization and rationalization of the organizational structure since <span class=\"xn-chron\">August 2022<\/span>.<\/li>\n<li>Net loss for the period decreased by <span class=\"xn-money\">RMB244.4 million<\/span> from <span class=\"xn-money\">RMB668.0 million<\/span> for the six months ended <span class=\"xn-chron\">30 June 2022<\/span> to <span class=\"xn-money\">RMB423.6 million<\/span> for the six months ended <span class=\"xn-chron\">30 June 2023<\/span>, primarily attributable to (i) a number of our drug candidates have completed clinical trials and advanced to the registration phase or commercial stages; (ii) the transfer of Trodelvy<sup>\u00ae<\/sup> related clinical and commercial activities to Gilead; and (iii) optimization and rationalization of the organizational structure.<\/li>\n<li>Cash and cash equivalents and bank deposits amounted to <span class=\"xn-money\">RMB2,540.2 million<\/span> as of <span class=\"xn-chron\">30 June 2023<\/span>.<\/li>\n<\/ul>\n<p><b>NON-IFRS MEASURE:<\/b><\/p>\n<ul type=\"disc\">\n<li>Adjusted loss for the period decreased by <span class=\"xn-money\">RMB196.8 million<\/span> from <span class=\"xn-money\">RMB523.7 million<\/span> for the six months ended <span class=\"xn-chron\">30 June 2022<\/span> to <span class=\"xn-money\">RMB326.9 million<\/span> for the six months ended <span class=\"xn-chron\">30 June 2023<\/span>, primarily attributable to narrowed IFRS loss.<\/li>\n<\/ul>\n<p><b>Conference Call Information<\/b><\/p>\n<p>The English session of the conference call will be held at <span class=\"xn-chron\">9:00 AM<\/span> on <span class=\"xn-chron\">August 24, 2023<\/span> Beijing Time (<span class=\"xn-chron\">9:00 PM<\/span> U.S. Eastern Time on <span class=\"xn-chron\">August 23, 2023<\/span>) and the Mandarin session of the conference call will be held at <span class=\"xn-chron\">3:30 PM<\/span> Beijing Time on the same day (<span class=\"xn-chron\">3:30 AM<\/span> U.S. Eastern Time on <span class=\"xn-chron\">August 24, 2023<\/span>).<\/p>\n<p><b>The conference calls can be accessed by the following links:<\/b><\/p>\n<p><b>For English Session:<\/b><\/p>\n<p><b>Time: <\/b><span class=\"xn-chron\">9:00 AM<\/span> Beijing Time, <span class=\"xn-chron\">Thursday, August 24, 2023<\/span><\/p>\n<p><b>Pre-Registration Link:&nbsp;https:\/\/www.acecamptech.com\/eventDetail\/60504030<\/b><\/p>\n<p><b>Webcast Link: <a href=\"https:\/\/www.acecamptech.com\/meeting_live\/70505775\/4998?event_id=60504030\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/www.acecamptech.com\/meeting_live\/70505775\/4998?event_id=60504030<\/a><\/b><\/p>\n<p>Alternatively, participants may dial in to the conference call using below dial-in information:<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody readability=\"3\">\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">United States:<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">+1-646-2543594(EN)<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Chinese Mainland:<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"2\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">+86-10-58084166(EN)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"prngen2\" colspan=\"2\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">+86-10-58084199(CN)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"2\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Hong Kong, China:<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"2\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">+852-30051313(EN)<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">+852-30051355(CN)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"4\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">United Kingdom:<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">International:<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"2\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">+44-20-76600166(EN)<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">+1-866-6363243(EN)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Password:<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">756491<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p><b>For Mandarin Session:<\/b><\/p>\n<p><b>Time: <\/b><span class=\"xn-chron\">3:30 PM<\/span> Beijing Time, <span class=\"xn-chron\">Thursday, August 24, 2023<\/span><\/p>\n<p><b>Webcast Link: <a href=\"https:\/\/s.comein.cn\/A12FL\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/s.comein.cn\/A12FL<\/a><\/b><\/p>\n<p>Alternatively, participants may dial into the conference call using below dial-in information:<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody readability=\"4\">\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">United States:<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">+1-202-5524791<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Chinese Mainland:<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"2\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">+86-400-188-8938<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"2\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><\/td>\n<td class=\"prngen2\" colspan=\"2\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">+86-10-53827720<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">+86-10-53560182<\/span><\/p>\n<\/td>\n<\/tr>\n<tr readability=\"6\">\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Hong Kong, China:<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">Taiwan, China:<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"2\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">+852-57006920<\/span><\/p>\n<p class=\"prnml4\"><span class=\"prnews_span\">+886-277031747<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Singapore:<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"2\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">+65-31586120<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">United Kingdom:<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"2\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">+44-2034816288<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">Password:<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\">684433<\/span><\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p>The replay of English session will be available shortly after the call and can be accessed by visiting the Company&#8217;s website at <a href=\"http:\/\/www.everestmedicines.com\/\" target=\"_blank\" rel=\"nofollow noopener\">http:\/\/www.everestmedicines.com<\/a>.<\/p>\n<p><b>About Everest Medicines<\/b><\/p>\n<p>Everest Medicines is a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules, many of which are in late-stage clinical development. The Company&#8217;s therapeutic areas of interest include renal diseases, infectious diseases, mRNA platform and autoimmune disorders.<\/p>\n<p><b>Forward-Looking Statements:<\/b><\/p>\n<p>This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as &#8220;will,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;future,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;confident&#8221; and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>SHANGHAI, Aug. 24, 2023 \/PRNewswire\/ &#8212; Everest Medicines (HKEX 1952.HK, &#8220;Everest&#8221;, or the &#8220;Company&#8221;), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2023, along with a corporate update. &#8220;We are pleased to have achieved a number of critical [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-21420","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Everest Medicines Announces Interim Results for First Half of 2023 - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=21420\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest Medicines Announces Interim Results for First Half of 2023 - My Blog\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, Aug. 24, 2023 \/PRNewswire\/ &#8212; Everest Medicines (HKEX 1952.HK, &#8220;Everest&#8221;, or the &#8220;Company&#8221;), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2023, along with a corporate update. &#8220;We are pleased to have achieved a number of critical [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=21420\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-24T00:15:00+00:00\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"15 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=21420#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=21420\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Everest Medicines Announces Interim Results for First Half of 2023\",\"datePublished\":\"2023-08-24T00:15:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=21420\"},\"wordCount\":2966,\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=21420\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=21420\",\"name\":\"Everest Medicines Announces Interim Results for First Half of 2023 - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"datePublished\":\"2023-08-24T00:15:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=21420#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=21420\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=21420#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest Medicines Announces Interim Results for First Half of 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Everest Medicines Announces Interim Results for First Half of 2023 - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=21420","og_locale":"en_US","og_type":"article","og_title":"Everest Medicines Announces Interim Results for First Half of 2023 - My Blog","og_description":"SHANGHAI, Aug. 24, 2023 \/PRNewswire\/ &#8212; Everest Medicines (HKEX 1952.HK, &#8220;Everest&#8221;, or the &#8220;Company&#8221;), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2023, along with a corporate update. &#8220;We are pleased to have achieved a number of critical [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=21420","og_site_name":"My Blog","article_published_time":"2023-08-24T00:15:00+00:00","author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=21420#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=21420"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Everest Medicines Announces Interim Results for First Half of 2023","datePublished":"2023-08-24T00:15:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=21420"},"wordCount":2966,"articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=21420","url":"https:\/\/transmediavictoria.net.au\/?p=21420","name":"Everest Medicines Announces Interim Results for First Half of 2023 - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"datePublished":"2023-08-24T00:15:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=21420#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=21420"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=21420#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Everest Medicines Announces Interim Results for First Half of 2023"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/21420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21420"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/21420\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}